Rocket Pharmaceuticals, Inc. (RCKT) — Company Research

Last Updated: 6 September 2026

Rocket Pharmaceuticals is a Cranbury, New Jersey gene-therapy developer that spent eight years and roughly $1.4bn of cumulative losses getting a first medicine approved — and reached that milestone in March 2026 with a market capitalisation of under half a billion dollars. The company sits at an unusual junction. It now owns an FDA-approved therapy, KRESLADI, and has already converted the priority review voucher that came with it into $180m of cash. It has also just restarted the pivotal trial that a patient death shut down in May 2025, with three patients through the safety window and no repeat of the complication. Against that, it still recognises no revenue at all, burns roughly $170m a year, and trades at an enterprise value materially below the cash on its balance sheet. This report sets out what the filings say, without opinions on whether the shares are cheap.

1. Company Snapshot

Field	Value
Legal name	Rocket Pharmaceuticals, Inc.
Ticker / exchange	RCKT, Nasdaq Global Market
Headquarters	Cranbury, New Jersey, United States
Sector	Healthcare — clinical-stage gene therapy (AAV and lentiviral)
Market cap	~$424m (109.8m shares at the $3.86 close on 4 September 2026)
Revenue (FY2025)	$0m — no revenue recognised in any year since 2018
Net loss (FY2025)	$223.1m, or $(2.01) per diluted share
Cash and investments	$283.7m at 30 June 2026; runway guided into Q2 2028
Borrowings	Nil. No debt outstanding since 2021
Employees	202 full-time at 31 December 2025 (195 US, 6 Spain, 1 Italy)
CEO / Leadership	Gaurav Shah, M.D., co-founder and Chief Executive Officer since January 2018; Aaron Ondrey, Chief Financial Officer since March 2024
Approved products	One — KRESLADI (marnetegragene autotemcel), accelerated approval 27 March 2026

Sources: Rocket Pharmaceuticals FY2025 Form 10-K (filed 26 February 2026), Q2 2026 results release (10 August 2026), and SEC XBRL company facts.

2. Bull Case and Bear Case

Bull Case

• An approval finally in hand: KRESLADI received FDA accelerated approval on 27 March 2026 for paediatric severe leukocyte adhesion deficiency-I, after a June 2024 complete response letter on manufacturing. Eight years of platform work now has a regulatory precedent behind it.
• The voucher was monetised immediately: the rare paediatric disease priority review voucher awarded on approval was sold for $180m gross, closing 12 June 2026. That is non-dilutive cash worth roughly 42% of the entire current market capitalisation.
• Danon is back on track with clean safety: all three patients dosed under the modified Phase 2 protocol at the recalibrated 3.8x10^13 GC/kg dose completed the protocol-defined observation period with no thrombotic microangiopathy and no capillary leak syndrome — the exact complication that caused the May 2025 hold.
• Enterprise value below net cash: with $283.7m of cash and investments, no borrowings and a $424m market capitalisation, the enterprise value is roughly $140m. The market is currently attributing very little to an approved product plus four clinical programmes.
• Cost base cut hard and runway extended: the July 2025 reorganisation removed about 30% of staff; FY2025 R&D fell to $142.0m from $171.2m and G&A to $86.5m from $102.0m. Guided runway moved from "into Q2 2027" in February 2026 to "into Q2 2028" by August 2026.

Bear Case

• Still no revenue whatsoever: the income statement has shown $0 of revenue every year from 2018 through 2025, and KRESLADI patient onboarding is not expected to begin until Q4 2026. LAD-I is an ultra-rare condition, so even a successful launch will not produce meaningful scale.
• Danon is not de-risked, only restarted: Rocket is still "engaging the FDA" on dosing additional patients. Three patients is a small safety sample, and a further serious adverse event in the lead programme would be difficult to recover from.
• The AAV sector is in a sentiment downturn: Sarepta's Elevidys deaths, the FDA's suspension request and its revocation of Sarepta's platform-technology designation have chilled investor appetite for adeno-associated virus gene therapy across the board through 2025 and 2026.
• Burn still exceeds the balance sheet on a two-year view: trailing twelve-month operating cash outflow was $170.3m against $283.7m of cash. A $100m at-the-market equity facility with Cantor Fitzgerald was put in place in March 2026, and at a $3.86 share price any use of it is heavily dilutive.
• Optionality was deliberately narrowed: the Fanconi anaemia programme lost its EU marketing application in July 2025 and its US biologics licence application in October 2025, and the pyruvate kinase deficiency programme was deprioritised. Two late-stage shots on goal were removed to fund the cardiovascular platform.

3. Revenue Segments

Rocket manages the business as a single operating segment and recognises no revenue, so the table below sets out the therapeutic categories the company reports against rather than a revenue split. Every line is currently 0% of revenue.

Segment / category	% of revenue	What it is
AAV cardiovascular platform	0% — no revenue recognised	The company's declared strategic priority since July 2025. Adeno-associated virus therapies delivered by intravenous infusion for inherited cardiomyopathies: RP-A501 (Danon disease), RP-A601 (PKP2-ACM) and RP-A701 (BAG3-DCM).
Lentiviral haematology — commercial	0% — no revenue recognised	KRESLADI (marnetegragene autotemcel), the approved ex vivo lentiviral therapy for paediatric severe LAD-I. Commercial availability and patient onboarding anticipated to begin in Q4 2026 through a limited network of qualified treatment centres.
Lentiviral haematology — deprioritised	0% — no revenue recognised	RP-L102 for Fanconi anaemia (both regulatory filings withdrawn in 2025, partnering under consideration) and RP-L301 for pyruvate kinase deficiency (Phase 1 complete, RMAT designated, no committed timeline).
Non-operating cash generation	0% — recorded as other income, not revenue	The $180m sale of the KRESLADI priority review voucher, which closed on 12 June 2026 and produced a $178.2m gain in the Q2 2026 income statement. Voucher sales are one-off and are not classified as revenue.

4. Business Model and Moat

How it makes money. Today, it does not. Rocket has no product revenue, no collaboration revenue and no royalty stream. Every dollar spent since 2018 has been funded by equity issuance, and more recently by the one-off $180m voucher sale. The intended model is orphan-drug economics: single-administration curative gene therapies for conditions affecting a few thousand people worldwide, priced in the seven figures per patient and delivered through a small number of specialist treatment centres. KRESLADI is the first test of whether that model closes for Rocket.

What the moat is supposed to be. Two things. First, manufacturing: Rocket built its own 50,000 sq ft AAV cGMP facility inside a 103,720 sq ft Cranbury campus, which matters because the June 2024 complete response letter on KRESLADI was a chemistry-and-manufacturing rejection, not an efficacy one. Owning the process is what allowed the resubmission. Second, disease selection: the company deliberately targets monogenic conditions where the causal gene is unambiguous and there is either no approved therapy or only a transplant option, which limits the number of competitors willing to invest.

Why the moat is contested. Regulatory precedent in AAV gene therapy is not owned by anyone, and the FDA demonstrated in 2025 that a platform-technology designation can be revoked. Rocket's remaining defensive asset is therefore its data and its manufacturing know-how rather than any structural barrier. In practice, the binding constraint is capital: a clinical-stage company with a two-year cash runway competes for the same rare-disease patients as Ultragenyx and Krystal Biotech, both of which already fund development from product revenue.

5. Financial Health

Rocket has never recognised revenue. The annual series below is therefore a loss-and-liquidity table rather than a growth table, and the per-share figures are the meaningful line. All figures are taken from the company's own results releases and from SEC XBRL company facts filed with the Form 10-K.

Fiscal Year	Revenue ($m)	YoY %	GAAP EPS	Adjusted EPS	Dividend/share	Long-term debt (YE)
FY2021	$0m	n/a	$(2.67)	$(2.67)†	Nil	$0m‡
FY2022	$0m	n/a	$(3.26)	$(3.26)†	Nil	$0m‡
FY2023	$0m	n/a	$(2.92)	$(2.92)†	Nil	$0m‡
FY2024	$0m	n/a	$(2.73)	$(2.73)†	Nil	$0m‡
FY2025	$0m	n/a	$(2.01)	$(2.01)†	Nil	$0m‡

† Rocket publishes no adjusted or non-GAAP earnings measure in any period. The GAAP figure is repeated so the column is not left blank.

‡ Rocket has had no borrowings outstanding since its convertible notes were extinguished during 2021 (the XBRL convertible-note balance falls to zero at 30 June 2021 and stays there). The balance sheet does carry a finance-lease obligation on the Cranbury facility of $21.3m at 30 June 2026 and operating-lease liabilities of $3.5m; neither is debt in the borrowing sense. Aggregator "total debt" figures of roughly $24.8m are that lease total.

Quarter / Half	Revenue ($m)	Adjusted EPS	GAAP EPS
Q2 2026 (to 30 Jun 2026)	$0m	$1.08†	$1.08
Q1 2026 (to 31 Mar 2026)	$0m	$(0.42)†	$(0.42)
Q4 2025 (to 31 Dec 2025)	$0m	$(0.38)†	$(0.38)
Q3 2025 (to 30 Sep 2025)	$0m	$(0.45)†	$(0.45)
Q2 2025 (to 30 Jun 2025)	$0m	$(0.62)†	$(0.62)
FY2025 total	$0m	$(2.01)†	$(2.01)

The Q2 2026 profit is entirely non-operating. Reported net income was $123.2m, driven by a $178.2m gain on the priority review voucher sale; underneath it, R&D was $29.5m and G&A $17.4m, both sharply below the $42.7m and $25.0m of Q2 2025. Basic EPS was $1.09 and diluted $1.08. On a trailing twelve-month basis the company remains loss-making at $(0.17) per diluted share, and generated an operating cash outflow of $170.3m against capital expenditure of only $0.1m. Depreciation and amortisation over the same twelve months was $7.6m. Cash and investments moved from $188.9m at 31 December 2025 to $144.4m at 31 March 2026 and then to $283.7m at 30 June 2026 on receipt of the voucher proceeds.

6. Valuation Metrics

Raw metrics, September 2026. Not opinions on whether the stock is cheap or expensive.

Metric	Value
Market cap	~$424m (109,774,597 shares at the $3.86 close on 4 September 2026)
Enterprise value	~$140m (market cap ~$424m + borrowings $0m − cash and short-term investments $283.7m per the 30 June 2026 balance sheet). Enterprise value sits below net cash because the equity is capitalised at less than the cash it holds plus a negative value for the burn.
Trailing P/E (GAAP)	n/m — trailing twelve-month diluted EPS is $(0.17), a loss. The only profitable quarter in the series, Q2 2026, was produced by a one-off $178.2m voucher gain rather than by operations.
P/E (forward)	n/m — consensus forward EPS is $(1.30), a loss. Rocket issues no earnings guidance.
P/S (TTM)	n/m — the company recognises no revenue, so the ratio has no denominator.
EV/EBITDA (TTM)	n/m — trailing twelve-month EBITDA is negative $184.0m (operating loss $191.6m plus depreciation and amortisation of $7.6m, the wider cash-flow-statement figure). A negative denominator makes the multiple meaningless.
P/FCF	n/m — trailing twelve-month free cash flow is negative $170.4m (operating cash flow $(170.3)m less capital expenditure of $0.1m). Capital spending has collapsed from $16.4m in FY2023 to $0.4m in FY2025 as the build-out finished.
52-week high	$5.45 intraday; $5.30 on a closing basis
52-week low	$2.53 intraday; $2.60 on a closing basis
Short interest (% of float)	16.4% (14,391,319 shares short against a 87,545,241-share free float), settlement date 14 August 2026. Short interest has roughly doubled as a proportion of the float over the past twelve months.
Days to cover	9.7 days on the same 14 August 2026 settlement, using average daily volume. This is unusually high and reflects thin liquidity rather than a large absolute short position.
Price/book	~1.1x (market cap ~$424m against shareholders' equity of $368.8m at 30 June 2026)

Price action can be followed on the ChartsView Live Charts page.

7. What Are They Building

RP-A501 for Danon disease. The lead asset and the reason the share price is where it is. An AAV9 gene therapy delivered by single intravenous infusion for an X-linked cardiomyopathy that typically kills male patients in their teens or twenties without a heart transplant. On 23 May 2025 the FDA placed the pivotal Phase 2 trial on clinical hold after a treated patient developed capillary leak syndrome with complement activation and subsequently died of an acute systemic infection. Rocket's investigation pointed at a novel immunosuppressive agent that had been added to the pre-treatment regimen specifically for the AAV9 Danon programme. The FDA lifted the hold on 20 August 2025, under three months later, authorising resumption at a recalibrated dose of 3.8x10^13 GC/kg in three sequential patients with a minimum four-week interval and an immunomodulatory regimen closer to the earlier paediatric cohort. All three were dosed and, as disclosed on 10 August 2026, all three cleared the protocol-defined observation window with no thrombotic microangiopathy and no capillary leak syndrome. A global natural history study has now enrolled more than 50 patients.

KRESLADI for LAD-I. Approved on 27 March 2026 under accelerated approval for paediatric patients with severe leukocyte adhesion deficiency-I caused by biallelic ITGB2 variants who lack an HLA-matched sibling donor. This is an ex vivo lentiviral therapy: the patient's own haematopoietic stem cells are harvested, corrected and reinfused. The route to approval was not smooth — the FDA issued a complete response letter in June 2024 over chemistry and manufacturing deficiencies, and the resubmission was only accepted in October 2025 with a 28 March 2026 goal date.

RP-A601 for PKP2-ACM. A Phase 1 AAV programme in plakophilin-2 arrhythmogenic cardiomyopathy, still enrolling to cover a broader severity range. Data presented at the American Society of Gene and Cell Therapy meeting in May 2025, from an April 2025 cutoff, showed increased PKP2 protein expression on cardiac biopsy in all three initial patients, improved desmosomal localisation, directional improvements in arrhythmia measures and right-ventricular function, and no dose-limiting toxicities through up to twelve months of follow-up. An FDA update on pivotal study design is guided for the second half of 2026.

RP-A701 for BAG3 dilated cardiomyopathy. The newest programme, using an AAVrh.74 capsid. The IND was cleared in 2025 and screening is under way for a multicentre dose-escalation study in adults; first patient dosing is now guided for the second half of 2026, having previously been indicated for mid-2026. BAG3-associated dilated cardiomyopathy is estimated to affect around 30,000 people in the United States with no disease-specific approved therapy. The programme arrived with the December 2022 acquisition of Renovacor and its Temple University licence.

What is no longer being built. RP-L102 for Fanconi anaemia lost its European marketing authorisation application in July 2025 and its US biologics licence application in October 2025, in both cases by voluntary withdrawal for strategic rather than safety reasons; Rocket says it will consider external partnerships. RP-L301 for pyruvate kinase deficiency completed Phase 1 with RMAT designation and encouraging haemoglobin responses in the paediatric cohort, but carries no committed development timeline.

8. Competitive Landscape

Peer	Market cap (September 2026)	Key 2025/2026 metric
Krystal Biotech (KRYS)	~$10.6bn	Trailing revenue of ~$440m from VYJUVEK, the approved topical gene therapy for dystrophic epidermolysis bullosa. The clearest illustration of what a commercialised rare-disease gene therapy is worth relative to a pre-revenue one.
uniQure (QURE)	~$3.1bn	Trailing revenue of ~$19m. The nearest large AAV-focused pure-play, with programmes in Huntington's disease and haemophilia B; valued at more than seven times Rocket on a comparable pre-commercial revenue base.
Beam Therapeutics (BEAM)	~$3.1bn	Trailing revenue of ~$156m, almost all collaboration income. A base-editing platform company rather than a conventional AAV developer, included as the benchmark for what platform optionality is priced at.
Sarepta Therapeutics (SRPT)	~$2.4bn	Trailing revenue of ~$1.97bn, yet capitalised at under 1.3x sales after the FDA requested suspension of Elevidys distribution, placed limb-girdle trials on hold following three patient deaths, revoked the company's platform-technology designation, and the company cut roughly 36% of staff.
Ultragenyx Pharmaceutical (RARE)	~$1.5bn	Trailing revenue of ~$717m across multiple approved rare-disease products. A diversified commercial rare-disease company now capitalised at roughly twice Rocket's cash balance.

The read-across from Sarepta matters more than the individual comparisons. A company with nearly $2bn of revenue trading at 1.3 times sales tells you what the market currently pays for AAV gene-therapy risk after a cluster of patient deaths. Rocket's own clinical hold arrived in the same window, and its equity has re-rated to an enterprise value below net cash as a result. Set against that, Krystal at roughly 24 times sales shows the sector is not uniformly derated — commercialised, safe and growing is still valued generously.

9. Insider Activity

Chief Executive Gaurav Shah, who co-founded Rocket and has led it since January 2018, is the only named officer with disclosed 2026 Form 4 activity found in this review. All of the transactions below are dispositions connected to equity compensation rather than discretionary open-market selling: two are shares withheld or sold to satisfy tax on restricted stock unit vesting, and the third covers the exercise cost and tax on an option exercise that simultaneously increased his holding by 76,490 shares. No open-market purchases by any insider were identified.

Name	Date	Type	Shares	Price	Value	Plan Type
Gaurav Shah (CEO)	18 Aug 2026	Disposition	2,293	$3.381	~$7,753	RSU tax withholding
Gaurav Shah (CEO)	13 Aug 2026	Disposition	2,837	$3.381	~$9,592	RSU tax withholding
Gaurav Shah (CEO)	21 May 2026	Sale to cover	55,684	~$3.09	~$171,840	Option exercise cost and tax
Gaurav Shah (CEO)	21 May 2026	Acquisition	76,490	Exercise price	~$129,344	Stock option exercise

Shares outstanding have grown steadily from 106,453,818 at 31 December 2024 to 109,539,424 at 30 June 2026 — a little under 3% over eighteen months, which is modest for a pre-revenue biotech and reflects the fact that the December 2024 offering and pre-funded warrant placement, not 2026 issuance, did the heavy lifting.

10. Key Risks

• Liquidity and dilution: Rocket recognises no revenue and burned $170.3m of operating cash over the last twelve months against $283.7m of cash and investments. Guided runway reaches into Q2 2028, which means a financing decision arrives well before the Danon programme could plausibly be approved. A $100m at-the-market facility with Cantor Fitzgerald has been in place since March 2026, and issuing equity near a $3.86 share price would be materially dilutive.
• Repeat safety events in the lead programme: the May 2025 patient death produced a three-month clinical hold and a permanent reset of the Danon protocol. Only three patients have been dosed under the revised regimen. A further serious adverse event would very likely end the programme that accounts for most of the equity's optionality.
• Regulatory pathway not yet agreed: the FDA lifted the hold but Rocket is still "engaging" the agency on dosing additional patients and completing the pivotal trial. The size, endpoints and duration of that trial are undetermined, and the guided update is only a general commitment to the second half of 2026.
• Commercial execution on an ultra-rare indication: KRESLADI treats a condition affecting a very small number of children. Patient onboarding does not begin until Q4 2026, will run through a limited network of qualified treatment centres, and depends on payer reimbursement for a one-time high-cost therapy. Approval does not guarantee uptake.
• Sector-wide AAV sentiment and FDA posture: the Sarepta episode showed the FDA is willing to suspend distribution of an approved gene therapy, halt multiple trials and revoke a platform designation. That regulatory temperature applies to Rocket's entire cardiovascular pipeline regardless of its own data.
• Concentrated pipeline after the reorganisation: the July 2025 restructuring removed about 30% of the workforce and shelved the Fanconi anaemia and pyruvate kinase deficiency programmes. The company is now effectively a bet on three AAV cardiac assets plus one approved ultra-orphan product.
• Thin liquidity and elevated short interest: 16.4% of the free float is sold short with 9.7 days to cover. In a sub-$500m company that combination amplifies moves in both directions and can make orderly financing harder.

11. Recent Developments

• 10 Aug 2026 — Q2 2026 results and a clean Danon safety readout. Net income of $123.2m ($1.09 basic, $1.08 diluted) driven by the $178.2m voucher gain; R&D down to $29.5m and G&A to $17.4m; cash and investments $283.7m; runway extended to "into Q2 2028". All three patients dosed under the modified RP-A501 protocol cleared the safety observation period with no thrombotic microangiopathy or capillary leak syndrome.
• 12 Jun 2026 — Priority review voucher sale closes. The rare paediatric disease voucher awarded with the KRESLADI approval was sold for $180m in gross proceeds, transforming the balance sheet without issuing a share.
• 07 May 2026 — Q1 2026 results. Net loss of $47.6m, or $(0.42) per share; R&D $31.5m; G&A $17.1m; cash and investments down to $144.4m. The definitive agreement to sell the voucher was announced alongside.
• 27 Mar 2026 — FDA approves KRESLADI. Accelerated approval for marnetegragene autotemcel in paediatric patients with severe LAD-I, delivered on the 28 March 2026 goal date. Rocket's first approved product in eight years as a gene-therapy developer.
• 26 Feb 2026 — FY2025 results and Form 10-K. Full-year net loss of $223.1m, or $(2.01) per share, down from $258.7m; R&D $142.0m against $171.2m; cash and investments $188.9m; runway then guided only "into Q2 2027". Headcount disclosed at 202 full-time employees.
• 06 Nov 2025 — Q3 2025 results. Net loss of $50.3m, or $(0.45) per share, with R&D down to $34.1m from $42.3m a year earlier as the restructuring took effect. Rocket also confirmed it had voluntarily withdrawn the US biologics licence application for RP-L102 in Fanconi anaemia on strategic grounds, with no complete response letter involved.
• 13 Oct 2025 — FDA accepts the KRESLADI resubmission. The agency accepted the resubmitted biologics licence application and set a 28 March 2026 goal date. The filing was supported by Phase 1/2 data showing 100% overall survival at twelve months post-infusion with all primary and secondary endpoints met.
• 20 Aug 2025 — FDA lifts the RP-A501 clinical hold. Under three months after imposition, with a recalibrated 3.8x10^13 GC/kg dose, sequential dosing of three patients at four-week intervals and a revised immunomodulatory regimen.
• 24 Jul 2025 — Strategic reorganisation. Roughly 30% of the workforce cut, about 80 people, at a cost of around $3.5m mostly in severance, with twelve-month operating expenses guided down by nearly 25%. The pipeline was reprioritised onto the AAV cardiovascular platform, and the European marketing application for RP-L102 was withdrawn.
• 23 May 2025 — Clinical hold after a patient death. The FDA halted the pivotal Danon disease trial after a treated patient developed capillary leak syndrome with complement activation and later died of an acute systemic infection. This is the event from which the current share price descends.

12. Key Dates

• 10 Sep 2026 — Dr Gaurav Shah takes part in a fireside chat at the 2026 Cantor Global Healthcare Conference, 1:00 PM Eastern, webcast via the investor relations site.
• 15 Sep 2026 — Fireside chat at the Morgan Stanley 24th Annual Global Healthcare Conference, 9:15 AM Eastern, with management investor meetings alongside.
• Expected 2H 2026 — FDA regulatory-pathway update on RP-A501 covering the dosing of additional Danon patients and completion of the pivotal trial.
• Expected 2H 2026 — Investor webinar giving a comprehensive Danon disease programme update, confirmed as on track in the Q2 2026 release.
• Expected 2H 2026 — FDA update on the planned pivotal study design for RP-A601 in PKP2-ACM, and first patient dosing in the RP-A701 BAG3-DCM Phase 1.
• Expected Nov 2026 — Q3 2026 results. No date has been announced; Q3 2025 was reported on 6 November 2025.
• Expected Q4 2026 — KRESLADI commercial availability and the start of patient onboarding through qualified treatment centres.

There is no outstanding PDUFA date for any Rocket programme following the March 2026 KRESLADI approval. Scheduled macro events that move healthcare and small-cap biotech more broadly are listed on the ChartsView Economic Calendar, and readers can discuss this report in the ChartsView Forum.

---

Disclaimer: This research is produced by ChartsView for educational and informational purposes only. It does not constitute financial advice or a recommendation to buy or sell any security. All information is sourced from publicly available company filings, press releases, and official data. ChartsView does not use analyst opinions or third-party ratings. Always conduct your own due diligence and consider your personal financial situation before making investment decisions. Past performance is not indicative of future results.